Wikipedia -WSS

Wikipedia

author：fashion 2025-09-28 23:29:29 - browse：73714

Courtesy Guardant Health

An independent panel of advisers to the Food and Drug Administration recommended the agency approve Guardant Health’s blood-based colon cancer detection test. If the agency follows the recommendation, it will clear an early hurdle for the test’s broader adoption.

The expert panel spent hours listening to presentations from Guardant, the FDA, and members of the public before voting on the screening test, called Shield. The panel’s nine voting members then voted on whether the test was safe, effective, and whether its benefits outweigh its risks, with eight, six, and seven panelists endorsing those views, respectively.

FDA approval is a requirement for winning coverage from the Centers for Medicare and Medicaid Services, which could be the difference between Guardant’s test becoming widespread — or irrelevant. In 2021, CMS denied coverage for Epi proColon, a different blood-based colon cancer test approved by the FDA. Soon after, the test’s maker, Epigenomics, announced that it would stop actively marketing the test, and last year the company announced a restructuring that included layoffs.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： FDA cancer chief on how to get things done: ‘Don’t tell anybody'

focus

WSS

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

Truvian presents data for its desktop blood

Healthy food access boosts outcomes in two studies

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

Truvian presents data for its desktop blood

Democrats decry new health bill for going easy on private equity

leisure time

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

White House drug czar issues call for 'recovery

How one medical school became remarkably diverse

White House drug czar issues call for 'recovery

BioMarin wins approval for gene therapy to treat hemophilia A

Biogen says it will cut costs by $700 million, slash 1,000 jobs

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Democrats decry new health bill for going easy on private equity

Walensky prepares to leave CDC — and Congress — behind

Device maker Teleflex to acquire urology company for $600M

explore

First transplant of an entire human eye performed

FDA reorg will put new emphasis on investigations, sources say

Rise in cancer among younger people worries and puzzles doctors

What to watch for from Zogenix and Amicus clinical trials

What to watch for from Zogenix and Amicus clinical trials

What causes rare myocarditis in young men after Covid vaccines?

focus

focus

entertainment

explore